Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Takeda
Lahey Clinic
Sotio Biotech Inc.
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Alaunos Therapeutics
BioNTech SE
Tempus AI
Incyte Corporation
Day One Biopharmaceuticals, Inc.
OHSU Knight Cancer Institute
ImmunoGenesis
Precision Biologics, Inc
Washington University School of Medicine
Thomas Jefferson University
M.D. Anderson Cancer Center
Thomas Jefferson University
Elevation Oncology
Columbia University
Georgetown University
Mayo Clinic
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
ImmunityBio, Inc.
NantBioScience, Inc.
Tyme, Inc
Novartis
Washington University School of Medicine
BioNTech SE
ImmunityBio, Inc.
NantCell, Inc.
NantCell, Inc.
Washington University School of Medicine
Pfizer
ADC Therapeutics S.A.
ImmunityBio, Inc.
ImmunityBio, Inc.
University of Pittsburgh
Academic and Community Cancer Research United
Peptomyc S.L.
Abramson Cancer Center at Penn Medicine
University of New Mexico
Georgetown University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Albert Einstein College of Medicine
Albert Einstein College of Medicine
University of California, San Francisco
University of Texas Southwestern Medical Center
MacroGenics
HonorHealth Research Institute